Veligrotug
As of the edition of 20 October 2026, Veligrotug is an antibody: marketed, first approved in 2026 (US); acts on IGF1R; US protection ends in 2038.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Antibody
- Brand name
- Lumvoa
- First approved
- 26 June 2026 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- miRagen Therapeutics
- Registered trials
- 8, 2 stopped early
- Disease areas
- Immune system; Eye; Hormones; Inherited and neonatal; Cancer; Blood and lymph
US protection
US protection ends in 2038.
US protection ends in 2038, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by miRagen Therapeutics. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Veligrotug.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IGF1R | Insulin-like growth factor 1 receptor | P08069 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 2 | 0 | 0 | 2 |
| Phase 3 | 4 | 4 | 0 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 8 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| miRagen Therapeutics | Originator and Lead sponsor of trials | 2022 to now |